The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.
J. Soria
No relevant relationships to disclose
F. G. De Braud
No relevant relationships to disclose
R. Cereda
Employment or Leadership Position - EOS GmbH
Stock Ownership - EOS GmbH
R. Bahleda
No relevant relationships to disclose
A. Delmonte
No relevant relationships to disclose
E. Angevin
No relevant relationships to disclose
A. Varga
No relevant relationships to disclose
C. Noberasco
No relevant relationships to disclose
E. Dall'O'
Employment or Leadership Position - SENDO Tech
N. Lassau
No relevant relationships to disclose
C. Dromain
No relevant relationships to disclose
M. Bellomi
No relevant relationships to disclose
F. Farace
No relevant relationships to disclose
F. Bertolini
No relevant relationships to disclose
M. Zucchetti
No relevant relationships to disclose
S. Marsoni
Employment or Leadership Position - SENDO Tech
Consultant or Advisory Role - EOS GmbH
M. G. Camboni
Employment or Leadership Position - EOS GmbH
Stock Ownership - EOS GmbH